#Elraglusib is an experimental drug that, when combined with standard chemotherapy, successfully doubled the one-year survival rate and reduced the overall risk of death by 38% in patients with metastatic #pancreatic #cancer during a randomized phase 2 clinical trial.
#Oncology #Immunology #Pharmaceutical #sflorg
https://www.sflorg.com/2026/04/ongy04152601.html
Scientific Frontline
npub1rc…q66yk
2026-04-15 12:37:21 UTC
Author Public Key
npub1rcnp4murz0fa4mq7jy7ukrtku6448rf7y9q5z4aatayvyl5yttkssq66ykSeen on
wss://relay.momostr.pinkPublished at
2026-04-15 12:37:21 UTCEvent JSON
{
"id": "25a9d6cbe43dec8fb952ba13102e2ad6520e6e9bc9a4301274c524126b9760a3",
"pubkey": "1e261aef8313d3daec1e913dcb0d76e6ab538d3e21414157bd5f48c27e845aed",
"created_at": 1776256641,
"kind": 1,
"tags": [
[
"t",
"pancreatic"
],
[
"t",
"oncology"
],
[
"t",
"sflorg"
],
[
"t",
"pharmaceutical"
],
[
"t",
"cancer"
],
[
"t",
"immunology"
],
[
"t",
"elraglusib"
],
[
"proxy",
"https://mastodon.social/@sflorg/116408755286200726",
"web"
],
[
"proxy",
"https://mastodon.social/users/sflorg/statuses/116408755286200726",
"activitypub"
],
[
"L",
"pink.momostr"
],
[
"l",
"pink.momostr.activitypub:https://mastodon.social/users/sflorg/statuses/116408755286200726",
"pink.momostr"
],
[
"-"
]
],
"content": "#Elraglusib is an experimental drug that, when combined with standard chemotherapy, successfully doubled the one-year survival rate and reduced the overall risk of death by 38% in patients with metastatic #pancreatic #cancer during a randomized phase 2 clinical trial. \n#Oncology #Immunology #Pharmaceutical #sflorg\nhttps://www.sflorg.com/2026/04/ongy04152601.html",
"sig": "b61fba6a6afaa3c85ce152cd13e42daf48183815c8879d8ec6643487f8c64d23eefda18ddf07a63b4f0b81da86358e7e5d231eaf1c9c612fbcd761bcc2ce79a3"
}